Literature DB >> 3198303

Atenolol and/or nifedipine in effort angina: which is the treatment of choice for exercise coronary protection?

M Romano1, T Di Maro, G Carella, M R Cotecchia, M R Caiazzo, E de Arcangelis, M Chiariello, M Condorelli.   

Abstract

The authors performed a long-term, double-blind, crossover, randomized study on the effects of two drugs (atenolol, 100 mg/day, or nifedipine, 10 mg t.i.d.) when administered alone or in combination on the exercise tolerance in 10 patients with stable angina on effort (mean age 52 +/- 4 years, 8 males and 2 females) and documented significant (greater than or equal to 70%) obstructive coronary lesions at angiography. None of the drug treatments improved exercise duration or maximal sustained work load. Atenolol decreased significantly ST segment depression to -1 +/- 0.8 from -1.91 +/- 0.7, baseline and -2.05 +/- 0.5, placebo. Nifedipine was not better than placebo. The atenolol plus nifedipine treatment was better than placebo (p less than 0.001) or nifedipine alone (p less than 0.05) but was not more significantly efficacious than atenolol alone. Long-term management of exertional angina can be usefully performed using atenolol. The use of nifedipine at the present dose of 10 mg, although well tolerated, did not improve the ST signs of ischemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3198303

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

1.  Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina.

Authors:  S Wieshammer; M Hetzel; U Barnikel; M Höher; H Seibold; M Kochs; V Hombach
Journal:  Klin Wochenschr       Date:  1991-09-16

2.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

Review 3.  Evaluating symptoms to improve quality of life in patients with chronic stable angina.

Authors:  Jeffrey W Young; Sheila Melander
Journal:  Nurs Res Pract       Date:  2013-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.